Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), CH-1011 Lausanne, Switzerland.
Int J Mol Sci. 2022 May 10;23(10):5343. doi: 10.3390/ijms23105343.
The molecular analysis of circulating analytes (circulating tumor-DNA (ctDNA), -cells (CTCs) and -RNA (ctRNA)/exosomes) deriving from solid tumors and detected in the bloodstream-referred as liquid biopsy-has emerged as one of the most promising concepts in cancer management. Compelling data have evidenced its pivotal contribution and unique polyvalence through multiple applications. These data essentially derived from translational research. Therewith, data on liquid biopsy in basic research with preclinical models are scarce, a concerning lack that has been widely acknowledged in the field. This report aimed to comprehensively review the available data on the topic, for each analyte. Only 17, 17 and 2 studies in basic research investigated ctDNA, CTCs and ctRNA/exosomes, respectively. Albeit rare, these studies displayed noteworthy relevance, demonstrating the capacity to investigate questions related to the biology underlying analytes release that could not be explored via translational research with human samples. Translational, clinical and technological sectors of liquid biopsy may benefit from basic research and should take note of some important findings generated by these studies. Overall, results underscored the need to intensify the efforts to conduct future studies on liquid biopsy in basic research with new preclinical models.
循环分析物（循环肿瘤 DNA [ctDNA]、循环肿瘤细胞 [CTC] 和循环 RNA [ctRNA]/外泌体）的分子分析源自血流中的实体瘤，并在被称为液体活检的检测中被发现，这已成为癌症管理中最有前途的概念之一。令人信服的数据通过多种应用证明了其关键贡献和独特的多功能性。这些数据主要源自转化研究。然而，关于基础研究中使用临床前模型的液体活检数据非常有限，这一令人担忧的缺乏在该领域已得到广泛认可。本报告旨在全面审查每个分析物的相关主题的现有数据。只有 17、17 和 2 项基础研究分别调查了 ctDNA、CTC 和 ctRNA/外泌体。尽管很少，但这些研究显示出了值得注意的相关性，证明了它们有能力研究与分析物释放背后的生物学相关的问题，而这些问题无法通过使用人类样本进行转化研究来探索。液体活检的转化、临床和技术领域可能受益于基础研究，并应注意到这些研究产生的一些重要发现。总的来说，结果强调了需要加强努力，在基础研究中使用新的临床前模型开展未来的液体活检研究。
